Good Life Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 11.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,309 shares of the biopharmaceutical company’s stock after selling 2,013 shares during the quarter. Good Life Advisors LLC’s holdings in Pfizer were worth $588,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Stillwater Capital Advisors LLC lifted its position in shares of Pfizer by 1.6% during the second quarter. Stillwater Capital Advisors LLC now owns 372,131 shares of the biopharmaceutical company’s stock worth $12,500,000 after purchasing an additional 5,876 shares during the last quarter. Beacon Financial Group increased its stake in shares of Pfizer by 2.3% during the second quarter. Beacon Financial Group now owns 228,070 shares of the biopharmaceutical company’s stock valued at $7,670,000 after buying an additional 5,027 shares during the period. First Command Bank increased its stake in shares of Pfizer by 131.5% during the second quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock valued at $804,000 after buying an additional 13,596 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Pfizer during the second quarter valued at $534,000. Finally, Stock Yards Bank & Trust Co. increased its stake in shares of Pfizer by 0.7% during the second quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock valued at $4,159,000 after buying an additional 832 shares during the period. Institutional investors own 69.75% of the company’s stock.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last quarter. 0.06% of the stock is owned by insiders.

PFE has been the topic of several research reports. BMO Capital Markets restated a “buy” rating and set a $39.00 price target (up previously from $37.00) on shares of Pfizer in a research note on Thursday, October 19th. Barclays set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $38.83.

Pfizer Inc. (NYSE PFE) opened at $36.54 on Tuesday. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $217,800.00, a PE ratio of 22.42, a price-to-earnings-growth ratio of 2.44 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities research analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

Pfizer announced that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.72%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is 78.53%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/16/good-life-advisors-llc-has-588000-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.